Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) have been given a consensus recommendation of “Moderate Buy” by the six brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $53.50.

Several research firms have weighed in on SLN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Friday, July 17th. Morgan Stanley upped their target price on Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Wednesday, June 17th. Finally, Cantor Fitzgerald started coverage on shares of Silence Therapeutics in a report on Wednesday, June 24th. They issued an “overweight” rating on the stock.

Silence Therapeutics Price Performance

Shares of Silence Therapeutics stock opened at $14.59 on Monday. The company’s fifty day simple moving average is $12.06 and its two-hundred day simple moving average is $8.46. Silence Therapeutics has a 12-month low of $4.19 and a 12-month high of $17.58. The firm has a market cap of $878.46 million, a PE ratio of -11.40 and a beta of 1.45.

Silence Therapeutics (NASDAQ:SLN) last posted its earnings results on Monday, August 10th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%. As a group, sell-side analysts expect that Silence Therapeutics will post -1.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Silence Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nantahala Capital Management LLC lifted its holdings in Silence Therapeutics by 48.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock worth $9,378,000 after buying an additional 500,000 shares during the period. Millennium Management LLC raised its position in shares of Silence Therapeutics by 121.0% in the 4th quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock worth $4,010,000 after acquiring an additional 361,080 shares in the last quarter. 5AM Venture Management LLC purchased a new position in shares of Silence Therapeutics in the 2nd quarter valued at approximately $5,228,676. UBS Group AG lifted its stake in shares of Silence Therapeutics by 34.5% in the 3rd quarter. UBS Group AG now owns 307,363 shares of the company’s stock valued at $1,595,000 after purchasing an additional 78,854 shares during the period. Finally, SG Americas Securities LLC boosted its position in shares of Silence Therapeutics by 11.8% during the first quarter. SG Americas Securities LLC now owns 286,698 shares of the company’s stock valued at $1,511,000 after purchasing an additional 30,358 shares in the last quarter. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.